Cargando…

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

INTRODUCTION: The safety of tofacitinib in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in clinical studies of ≤ 4 and 9.5 years, respectively. Post-marketing surveillance (PMS) data for tofacitinib from spontaneous and voluntary adverse event (AE) reports have been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burmester, Gerd R., Coates, Laura C., Cohen, Stanley B., Tanaka, Yoshiya, Vranic, Ivana, Nagy, Edward, Lazariciu, Irina, Chen, All-shine, Kwok, Kenneth, Fallon, Lara, Kinch, Cassandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469130/ https://www.ncbi.nlm.nih.gov/pubmed/37458964 http://dx.doi.org/10.1007/s40744-023-00576-8

Ejemplares similares

Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment
por: Winthrop, Kevin L., et al.
Publicado: (2021)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
por: Dougados, Maxime, et al.
Publicado: (2022)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
por: Burmester, Gerd R, et al.
Publicado: (2021)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
por: Winthrop, Kevin L., et al.
Publicado: (2022)

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
por: Pope, Janet E., et al.
Publicado: (2019)

Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
por: Xie, Rujia, et al.
Publicado: (2019)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
por: Kristensen, Lars E., et al.
Publicado: (2023)

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
por: Mease, Philip, et al.
Publicado: (2020)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
por: Gladman, Dafna D., et al.
Publicado: (2022)

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
por: Dikranian, Ara, et al.
Publicado: (2021)

Fracture in clinical studies of tofacitinib in rheumatoid arthritis
por: Hansen, Karen E., et al.
Publicado: (2022)

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis
por: van Vollenhoven, Ronald, et al.
Publicado: (2019)

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
por: Mariette, Xavier, et al.
Publicado: (2018)

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
por: Ly, Karen, et al.
Publicado: (2019)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
por: Coates, Laura C., et al.
Publicado: (2021)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
por: van der Togt, Céleste J.T., et al.
Publicado: (2022)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
por: Nash, Peter, et al.
Publicado: (2018)

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
por: Wollenhaupt, Jürgen, et al.
Publicado: (2019)

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany
por: Krüger, Klaus, et al.
Publicado: (2018)

Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis
por: Kim, Joon Wan, et al.
Publicado: (2013)

Distinguishing rheumatoid arthritis from psoriatic arthritis
por: Merola, Joseph F, et al.
Publicado: (2018)

94. Psoriatic arthritis, rheumatoid arthritis or both?
por: Zhang, Jean, et al.
Publicado: (2018)

Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study
por: Haraoui, Boulos, et al.
Publicado: (2022)

Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study
por: Leng, Xiaomei, et al.
Publicado: (2023)

Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
por: Bulatović Ćalasan, Maja, et al.
Publicado: (2013)

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2014)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
por: Li, Zhan-Guo, et al.
Publicado: (2018)

Precautions before starting tofacitinib in persons with rheumatoid arthritis
por: Swarnakar, Raktim, et al.
Publicado: (2022)

Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis
por: Mortezavi, Mahta, et al.
Publicado: (2023)

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
por: Winthrop, K L, et al.
Publicado: (2016)

Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension
por: Eder, Lihi, et al.
Publicado: (2023)

Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib
por: Inanc, Nevsun, et al.
Publicado: (2023)

Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
por: Dougados, Maxime, et al.
Publicado: (2023)

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
por: Burmester, Gerd R, et al.
Publicado: (2013)

Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
por: Mease, Philip J., et al.
Publicado: (2022)

Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany
por: Krüger, Klaus, et al.
Publicado: (2020)

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
por: Weitz, Jeffrey I, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3d60cktoppseb186ulgk887b4m